Recro Pharma, Inc. (REPH)

$2.09

-0.01 (-0.48%)
Rating:
Recommendation:
Buy
Symbol REPH
Price $2.09
Beta 1.115
Volume Avg. 0.13M
Market Cap 123.233M
Shares () -
52 Week Range 1.38-3.29
1y Target Est -
DCF Unlevered REPH DCF ->
DCF Levered REPH LDCF ->
ROE -32.45% Strong Sell
ROA -8.62% Neutral
Operating Margin -
Debt / Equity 310.83% Strong Buy
P/E -
P/B 3.17 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest REPH news


Ms. Geraldine Henwood
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.